Longeveron at $3.30 Ahead of Third-Quarter Results and Business Update
Key Facts
Longeveron shares closed at $3.30 on November 11, 2026, according to EL7 data. The following day, the company announced its third-quarter financial results and provided a business update, according to the headline of the release published via GlobeNewswire. The information available here does not include details of the quarter’s financial figures or the update, so it is not possible to determine whether the announcement changed investors’ assessment of the company. The release comes as markets follow the laromestrocel program, which failed to meet its primary endpoint in the ELPIS II trial. The program’s next steps also remain linked to the company’s discussions with the U.S. Food and Drug Administration.
Against the backdrop of the program, Longeveron said major adverse cardiovascular events recorded in the ELPIS II trial were about 31% lower in the laromestrocel arm than in the usual-care arm over 12 months of follow-up. The treatment arm recorded 12 events, compared with 19 in the untreated arm, according to the company. But an exploratory analysis using negative binomial regression did not reach statistical significance. This places the clinical-event signal alongside the trial’s failure on its primary endpoint, without making it a statistically established finding. The company had said further analyses of the full data were underway.
The company said it plans to discuss the ELPIS II results with the U.S. Food and Drug Administration to determine potential next steps for its treatment program for hypoplastic left heart syndrome. It added that the agency had indicated it was willing to meet after the study was complete, but details of a meeting date or its outcome are not available here. Longeveron had previously explained that right ventricular ejection fraction alone would not be sufficient to establish the efficacy required for regulatory approval. This constraint means the program’s regulatory path depends on a broader assessment of the data, according to the company. Any next step remains contingent on the discussions and analyses it said are ongoing.
Longeveron announced in September that it had begun reviewing available options to maximize shareholder value and said it would engage an investment bank as a strategic adviser to the process. The company linked that review to measures to preserve cash and control costs. Alongside its hypoplastic left heart syndrome program, the company cited its laromestrocel program for age-related clinical frailty. It said a Phase 2b trial showed an improvement in physical condition after 9 months compared with placebo. It also said it was pursuing funding sources and potential revenue opportunities to develop that program.